Original Article

Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the QR genetic polymorphism

Correspondence to: Philippe Moulin

High density lipoprotein (HDL)-associated paraoxonase (PON) seems to play a major role in the protection of low density lipoprotein (LDL) against peroxidation by HDL, and the partly purified enzyme exerts a dose-dependent protective effect. A common polymorphism of the human gene (192 QR) modulates paraoxonase activity but purified enzyme from either genotype is equally effective against LDL peroxidation. The inhibition of Cu²⁺-induced LDL peroxidation by HDL was monitored by lipid peroxide assay and change in LDL electrophoretic mobility. We show that HDL from type 2 diabetic patients with the QQ or RR genotype (n = 12 for each) reduce, to the same extent, both peroxide production (by 60.6 ± 20.0 and 63.9 ± 23.5%) and relative change in mobility (61.3 ± 21.8 and 61.4 ± 26.5%) despite a 6-fold difference in paraoxonase activity (47.4 ± 4.4 vs. 299.7 ± 23.7 U/l, P < 0.0001). Protection was, however, related to paraoxonase activity, but with a different efficiency in each group corresponding to a better protection per unit of enzyme in the QQ genotype group. Inactivation of PON activity by heating (56°C, 10 min) or by EDTA was totally without effect on protection, which remained correlated with the paraoxonase activity measured prior to inactivation.

In summary, these results suggest that the protein bearing both paraoxonase and arylesterase activities also possesses a third thermostable property, closely associated with paraoxon hydrolysis activity and unaffected by PON genetic variability.—Cao, H., A. Girard-Globa, F. Berthezene, and P. Moulin. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the QR genetic polymorphism. J. Lipid Res. 1999. 40: 133–139.

Supplementary key words: paraoxonase, HDL, LDL, peroxidation, atherosclerosis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Sarandol, S. Kirli, C. Akkaya, N. Ocak, E. Eroz, and E. Sarandol Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment J Psychopharmacol, November 1, 2007; 21(8): 857 - 863. [Abstract] [PDF]

				S. Deakin, X. Moren, and R. W. James HDL Oxidation Compromises its Influence on Paraoxonase-1 Secretion and its Capacity to Modulate Enzyme Activity Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1146 - 1152. [Abstract] [Full Text] [PDF]

				T. Kriska, G. K. Marathe, J. C. Schmidt, T. M. McIntyre, and A. W. Girotti Phospholipase Action of Platelet-activating Factor Acetylhydrolase, but Not Paraoxonase-1, on Long Fatty Acyl Chain Phospholipid Hydroperoxides J. Biol. Chem., January 5, 2007; 282(1): 100 - 108. [Abstract] [Full Text] [PDF]

				M. Graner, R. W. James, J. Kahri, M. S. Nieminen, M. Syvanne, and M.-R. Taskinen Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2429 - 2435. [Abstract] [Full Text] [PDF]

				J. F. Teiber, D. I. Draganov, and B. N. La Du Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH J. Lipid Res., December 1, 2004; 45(12): 2260 - 2268. [Abstract] [Full Text] [PDF]

				G. McKeown-Eyssen, C. Baines, D. E. Cole, N. Riley, R. F Tyndale, L. Marshall, and V. Jazmaji Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR Int. J. Epidemiol., October 1, 2004; 33(5): 971 - 978. [Abstract] [Full Text] [PDF]

				P. W. Connelly, G. F. Maguire, and D. I. Draganov Separation and quantitative recovery of mouse serum arylesterase and carboxylesterase activity J. Lipid Res., March 1, 2004; 45(3): 561 - 566. [Abstract] [Full Text] [PDF]

				M. Senti, M. Tomas, M. Fito, T. Weinbrenner, M.-I. Covas, J. Sala, R. Masia, and J. Marrugat Antioxidant Paraoxonase 1 Activity in the Metabolic Syndrome J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5422 - 5426. [Abstract] [Full Text] [PDF]

				N. Ferre, J. Camps, J. Fernandez-Ballart, V. Arija, M. M. Murphy, S. Ceruelo, E. Biarnes, E. Vilella, M. Tous, and J. Joven Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General Population Clin. Chem., September 1, 2003; 49(9): 1491 - 1497. [Abstract] [Full Text] [PDF]

				X. Wang, Z. Fan, J. Huang, S. Su, Q. Yu, J. Zhao, R. Hui, Z. Yao, Y. Shen, B. Qiang, et al. Extensive Association Analysis Between Polymorphisms of PON Gene Cluster With Coronary Heart Disease in Chinese Han Population Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 328 - 334. [Abstract] [Full Text] [PDF]

				G. K. Marathe, G. A. Zimmerman, and T. M. McIntyre Platelet-activating Factor Acetylhydrolase, and Not Paraoxonase-1, Is the Oxidized Phospholipid Hydrolase of High Density Lipoprotein Particles J. Biol. Chem., January 31, 2003; 278(6): 3937 - 3947. [Abstract] [Full Text] [PDF]

				N. Ferre, J. Camps, E. Prats, E. Vilella, A. Paul, L. Figuera, and J. Joven Serum Paraoxonase Activity: A New Additional Test for the Improved Evaluation of Chronic Liver Damage Clin. Chem., February 1, 2002; 48(2): 261 - 268. [Abstract] [Full Text] [PDF]

				P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I Circulation, November 6, 2001; 104(19): 2376 - 2383. [Full Text] [PDF]

				R. J. Brushia, T. M. Forte, M. N. Oda, B. N. La Du, and J. K. Bielicki Baculovirus-mediated expression and purification of human serum paraoxonase 1A J. Lipid Res., June 1, 2001; 42(6): 951 - 958. [Abstract] [Full Text]

				I. Leviev, S. Deakin, and R. W. James Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations J. Lipid Res., April 1, 2001; 42(4): 528 - 535. [Abstract] [Full Text]

				M. Senti, M. Tomas, J. Marrugat, R. Elosua, and f. t. REGICOR Investigators Paraoxonase1-192 Polymorphism Modulates the Nonfatal Myocardial Infarction Risk Associated With Decreased HDLs Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 415 - 420. [Abstract] [Full Text] [PDF]

				M. Tomas, M. Senti, F. Garcia-Faria, J. Vila, A. Torrents, M. Covas, and J. Marrugat Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2113 - 2119. [Abstract] [Full Text] [PDF]

				S. Sen-Banerjee, X. Siles, and H. Campos Tobacco Smoking Modifies Association Between Gln-Arg192 Polymorphism of Human Paraoxonase Gene and Risk of Myocardial Infarction Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2120 - 2126. [Abstract] [Full Text] [PDF]

				R. W. James, I. Leviev, and A. Righetti Smoking Is Associated With Reduced Serum Paraoxonase Activity and Concentration in Patients With Coronary Artery Disease Circulation, May 16, 2000; 101(19): 2252 - 2257. [Abstract] [Full Text] [PDF]

				C Aubo, M Senti, J Marrugat, M Tomas, J Vila, J Sala, and R Masia Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus Eur. Heart J., January 1, 2000; 21(1): 33 - 38. [Abstract] [PDF]